Alkem Laboratories Ltd - 539523 - Board recommends Final Dividend (AGM on August 27, 2021)
Alkem Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 25, 2021, inter alia, has recommended a final dividend of Rs. 5/- (Rupees Five only) per equity share of Rs. 2/- each for the financial year ended March 31, 2021, for the approval of the shareholders of the Company at the ensuing Annual General Meeting. Alkem Laboratories Ltd - 539523 - Results - Financial Results For Quarter And Year Ended March 31, 21
continuation of our letter dated 14th May, 2021 and pursuant to Regulation 30 read with Regulation 33 of the SEBI LODR (''Listing Regulations'') the Board of Directors of the Company, at its meeting held today, i.e. 25th May, 2021, has inter alia: . 1. Approved the Standalone and Consolidated Audited Financial Results for the quarter and financial year ended 31st March, 2021. Accordingly, we are enclosing herewith Standalone and Consolidated Audited Financial Results for the quarter and financial year ended 31st March, 2021 and the Auditor''s Report thereon. The Company hereby declares that the Auditors have expressed an unmodified opinion in the Audit Reports on Standalone and Consolidated Financial Results for the quarter and financial year ended 31st March, 2021. The meeting of the Board of Directors of the Company commenced at 11.00 A.M and concluded at 1.45 P.M Kindly take the same on record. Alkem Laboratories Ltd - 539523 - Outcome Of Board Meeting Dated 25/05/2021
The BOD at its meeting held today i.e. 25.05.21 has, inter alia approved the Standalone and Consolidated Audited Financial Statements for the quarter and FY ended 31.3.21 and other items as enclosed herewith. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we write to inform you that a conference call to discuss the Q4FY21 and FY21 financial results will be held on Tuesday, 25th May, 2021 at 04.30 p.m. Please find attached herewith the conference call details. Kindly take note of the same. Alkem Laboratories Ltd - 539523 - Board to consider FY21 results & Final Dividend on May 25, 2021
Alkem Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on May 25, 2021, inter alia:1. To consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended March 31, 2021; and2. To consider and recommend Final Dividend, if any, for the Financial Year ended March 31, 2021. Alkem Laboratories Ltd - 539523 - Board Meeting Intimation for Notice Of Meeting Of Board Of Directors Of The Company Scheduled To Be Held On 25Th May, 2021.
Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2021 ,inter alia, to consider and approve (i) to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2021; and (ii) to consider and recommend Final Dividend, if any, for the financial year ended 31st March, 2021. Kindly take note of the same. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
In furtherance to our intimation to the stock exchanges on 30th March 2021, that Alkem Laboratories Limited has subscribed to partnership interest to the extent of 12.5%in ABCD Technologies LLP (to be renamed as IndoHealth Services LLP), we hereby intimate that post admission of 9 new partners on 30th April 2021, in ABCD Technologies LLP, the partnership interest in ABCD Technologies LLP now stands revised at 6.45% entitling 6.45% share of profit/ loss and voting rights. We request you to kindly take this in your record and disseminate. Alkem Laboratories Ltd - 539523 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayAlkem Laboratories Ltd 2CINL00305MH1973PLC174201 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY AA+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: MANISH NARANG Designation: President Legal Company Secretary and Compliance Officer EmailId: manishnarang@alkem.com Name of the Chief Financial Officer: RAJESH DUBEY Designation: President Finance and CFO EmailId: rajeshdubey@alkem.com Date: 29/04/2021 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.Why the stock of Alkem Labs is a good Buy'
The stock is suitable for long-term investors, given multiple positives and reasonable valuation